全文获取类型
收费全文 | 22494篇 |
免费 | 2107篇 |
国内免费 | 477篇 |
专业分类
耳鼻咽喉 | 201篇 |
儿科学 | 205篇 |
妇产科学 | 552篇 |
基础医学 | 2284篇 |
口腔科学 | 184篇 |
临床医学 | 2364篇 |
内科学 | 3011篇 |
皮肤病学 | 209篇 |
神经病学 | 374篇 |
特种医学 | 591篇 |
外科学 | 2102篇 |
综合类 | 2145篇 |
一般理论 | 2篇 |
预防医学 | 1672篇 |
眼科学 | 54篇 |
药学 | 1754篇 |
10篇 | |
中国医学 | 457篇 |
肿瘤学 | 6907篇 |
出版年
2023年 | 479篇 |
2022年 | 856篇 |
2021年 | 1296篇 |
2020年 | 1012篇 |
2019年 | 1468篇 |
2018年 | 1485篇 |
2017年 | 1210篇 |
2016年 | 847篇 |
2015年 | 894篇 |
2014年 | 1881篇 |
2013年 | 1707篇 |
2012年 | 1221篇 |
2011年 | 1319篇 |
2010年 | 934篇 |
2009年 | 987篇 |
2008年 | 1178篇 |
2007年 | 943篇 |
2006年 | 727篇 |
2005年 | 569篇 |
2004年 | 522篇 |
2003年 | 390篇 |
2002年 | 238篇 |
2001年 | 268篇 |
2000年 | 236篇 |
1999年 | 229篇 |
1998年 | 182篇 |
1997年 | 171篇 |
1996年 | 181篇 |
1995年 | 147篇 |
1994年 | 148篇 |
1993年 | 106篇 |
1992年 | 72篇 |
1991年 | 61篇 |
1990年 | 50篇 |
1989年 | 64篇 |
1988年 | 42篇 |
1987年 | 43篇 |
1986年 | 34篇 |
1985年 | 100篇 |
1984年 | 125篇 |
1983年 | 96篇 |
1982年 | 126篇 |
1981年 | 86篇 |
1980年 | 78篇 |
1979年 | 73篇 |
1978年 | 45篇 |
1977年 | 29篇 |
1976年 | 33篇 |
1975年 | 27篇 |
1974年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
11.
A major advance was made to reduce the side effects of cancer therapy via the elucidation of the tumor-specific lytic path “hyperploid progression-mediated death” targeting retinoblastoma (Rb) or p53-mutants defective in G1 DNA damage checkpoint. The genetic basis of human cancers was uncovered through the cloning of the tumor suppressor Rb gene. It encodes a nuclear DNA-binding protein whose self-interaction is regulated by cyclin-dependent kinases. A 3D-structure of Rb dimer is shown, confirming its multimeric status. Rb assumes a central role in cell cycle regulation and the “Rb pathway” is universally inactivated in human cancers. Hyperploidy refers to a state in which cells contain one or more extra chromosomes. Hyperploid progression occurs due to continued cell-cycling without cytokinesis in G1 checkpoint-defective cancer cells. The evidence for the triggering of hyperploid progression-mediated death in RB-mutant human retinoblastoma cells is shown. Hence, the very genetic mutation that predisposes to cancer can be exploited to induce lethality. The discovery helped to establish the principle of targeted cytotoxic cancer therapy at the mechanistic level. By triggering the lytic path, targeted therapy with tumor specificity at the genetic level can be developed. It sets the stage for systematically eliminating side effects for cytotoxic cancer therapy. 相似文献
12.
13.
14.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献15.
《Biomaterials》2015
The human mutT homologue MTH1, a nucleotide pool sanitizing enzyme, represents a vulnerability factor and an attractive target for anticancer therapy. However, there is currently a lack of selective and effective platforms for the detection and inhibition of MTH1 in cells. Here, we demonstrate for the first time a gold nanoparticle (AuNP) flares-capped mesoporous silica nanoparticle (MSN) nanoplatform that is capable of detecting MTH1 mRNA and simultaneously suppressing MTH1 activity. The AuNP flares are made from AuNPs that are functionalized with a dense shell of MTH1 recognition sequences hybridized to short cyanine (Cy5)-labeled reporter sequences and employed to seal the pores of MSN to prevent the premature MTH1 inhibitors (S-crizotinib) release. Just like the pyrotechnic flares that produce brilliant light when activated, the resulting AuNP flares@MSN (S-crizotinib) undergo a significant burst of red fluorescence enhancement upon MTH1 mRNA binding. This hybridization event subsequently induces the opening of the pores and the release of S-crizotinib in an mRNA-dependent manner, leading to significant cytotoxicity in cancer cells and improved therapeutic response in mouse xenograft models. We anticipate that this nanoplatform may be an important step toward the development of MTH1-targeting theranostics and also be a useful tool for cancer phenotypic lethal anticancer therapy. 相似文献
16.
17.
《Annales médico-psychologiques》2022,180(8):773-779
Adolescent and young adult cancer – AYA – enters a period of life during which a dynamic developmental process takes place, particularly with the existential issues of separation-individualization and empowerment at stake. The experience of cancer is in fact a major ordeal, a major upheaval not only for the young person but also for his entire family. This review of the narrative literature aims to take stock of current knowledge on the psychological repercussions of serious illness on the AYA and his family. After presenting results, we will propose recommendations for the clinic and avenues for future research. 相似文献
18.
《Radiologia》2022,64(3):256-265
Breast cancer is the second most common cancer in Peruvian women. Due to limitations in national breast cancer screening programs, especially in rural areas, more than 50% of cases of breast cancer in Peru are diagnosed in advanced stages. In collaboration with a local clinic registered as a nongovernmental organization (CerviCusco), RAD-AID International aims to create a sustainable diagnostic structure to improve breast cancer screening in Cuzco. With the support of local, national, and international partners that have collaborated in analyzing radiological resources, raising awareness in the population, acquiring equipment, training clinical staff, and building referral networks, our teams of radiologists, included in the RAD-AID team, have participated in training CerviCusco staff in breast ultrasound, thus enabling additional training for radiology residents through a regulated international collaboration. 相似文献
19.
目的:分析手术治疗结节性甲状腺肿合并甲状腺癌的临床效果。方法:从2017年3月~2019年3月期间到我院接受治疗的结节性甲状腺肿合并甲状腺癌患者中选出60例完成此次研究,60例患者全部接受手术治疗,经1年的随访后对比两组患者接受治疗前后的生活质量变化情况及治疗效果。结果:接受治疗后患者的心理、身体、物质生活、社会关系等多项生活质量指标均优于治疗前,治疗前后的数据对比存在明显差异(P<0.05)。所有患者接受治疗后均为表现出较为明显的不良反应,其治疗存在较高安全性,总治疗有效率为87.50%(55/60)。结论:帮助结节性甲状腺肿合并甲状腺癌患者选择合理的手术方式,能够提高临床治疗效果,减少并发症。 相似文献
20.